LONDON, April 11, 2017 /PRNewswire/ -- The Western European molecular diagnostics (MDx) market will experience swift
Western European Molecular Diagnostics Market, 2015 Forecast to 2020, recent research from Frost & Sullivan's Life Sciences Growth Partnership Service program, examines the growth potential of the MDx market in Western Europe and the strategic measures taken by market majors such as Roche, Thermofisher, Siemens, Illumina and Agilent. The insight not only studies life science, IVD and research companies, but also players from the POCT segment in the region. The market, which stood at $1.79 billion in 2015, is expected to generate $3.08 billion by 2020, growing at a compound annual growth rate of 11.5 percent.
To know more about Frost & Sullivan's research and to sign up for our Growth Strategy Dialogue, a complimentary one-hour interactive session with Frost & Sullivan's thought leaders, please go to https://goo.gl/D81Ed1.
"MDx companies which fail to capitalise on opportunities presented through emerging trends and disruptive new business models will become late entrants in a market, where competition between existing products and new products with similar functionalities occur quickly", said Transformational Health Senior Research Analyst Saravanan Thangaraj. "Early entry offers several advantages in terms of wider market share grab, exclusivity for some period of time, and opportunities for emerging markets o cater to biologics manufacturing outsourcing."
Key trends in the Western European MDx market include:
"Companion diagnostics and pharmacogenomics will be the key to redefine treatment and expand the panel of diagnosis toward a particular disease, leading to personalised medicine," observed Sulaikha. "The field of POCT with MDx will be a key area of opportunity to watch."
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
Western European Molecular Diagnostics Market, 2015 Forecast to 2020MC62-52
Contact:Jana SchönebornCorporate Communications – EuropeP: +49 (0)69 77033 43E: firstname.lastname@example.org
http://ww2.frost.comtwitter: @FS_HealthcareLinkedIn: Transform Health
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/molecular-diagnostics-vendors-in-western-europe-leverage-innovation-and-need-for-point-of-care-testing-300437844.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!
Cardiopulmonary bypass is a technique which allows performing open heart surgical procedures in a ...
Acyclovir is an effective antiviral medication used primarily for treating the symptoms of herpes ...
Fasciotomy is a surgical procedure where the fascia is incised to relieve the compartmental ...View All